Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025 Kelsey M. Sumner, Emma K. Noble, Lauren B. Grant, Jessica R. Meeker, Vel Murugan, Lora Nordstrom, Stacey L. House, Rachel M. Presti, Emmanuel B. Walter, Olivia L. Williams, Elie A. Saade, David H. Canaday, Katherine V. Williams, Richard K. Zimmerman, F. Liaini Gross, Sara Valencia, Brian Gurbaxani, Nathaniel M. Lewis, Zhu-Nan Li, Vasiliy Mishin, Larisa Gubareva, Bin Zhou, Min Z. Levine, Brendan Flannery, Sascha Ellington Abstract ABSTRACTBackgroundRecombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines.Methods We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577 ). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. ResultsAmong the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients.ConclusionsRIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.